Description: Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.
Home Page: www.protagenic.com
PTIX Technical Analysis
149 Fifth Avenue
New York,
NY
10010
United States
Phone:
212 994 8200
Officers
| Name | Title |
|---|---|
| Dr. Garo H. Armen Ph.D. | Co-Founder & Exec. Chairman |
| Dr. Alexander Kenneth Arrow C.F.A., M.D. | CFO & Sec. |
| Dr. Andrew Slee | Chief Operating Officer |
| Dr. Robert Benjamin Stein M.D., Ph.D. | Chief Medical Officer & Director |
| Dr. David A. Lovejoy | Chief Scientific Officer, Scientific Founder & Scientific Advisor |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9968 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2016-01-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |